Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase III Trial of HIPEC in Platinum-Resistant Recurrent Ovarian Cancer
KCT0007111Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 3, randomised trial of 5-fluorouracil + nab-paclitaxel + cisplatin + interleukin-2 in ovarian cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Apr 2022; status: recruiting.
02
Drugs
5-fluorouracil + nab-paclitaxel + cisplatin + interleukin-2
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0007111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007111.